The Newsroom
Research·October 23, 2026 at 12:47 PM EDT·1 source

Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials

NVS -3.3%
NVS · last 30 trading days-1.8% since the news
News

What happened

  • Novartis said its multiple sclerosis treatment cut relapse rates by a third compared with a standard treatment in pivotal trials.
Relapse-rate reduction
by a third

Why it matters

The results could affect treatment choices and the competitive landscape for multiple sclerosis therapies, which matters to healthcare professionals and investors monitoring clinical differentiation.

Read more on YouBank

The Newsroom, ranked for your desk

About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.

Timeline

  1. EarlierOct 22
    Roche talks up Phase 3 success rate as it unveils pipeline cuts
  2. EarlierOct 23
    Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study
  3. EarlierOct 23
    Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pause
  4. EarlierOct 23
    Novartis Multiple Sclerosis Pill Missed Expectations in Key Study
  5. First reported by STATOct 23
    Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials

Sources (1)

  1. STATOct 23
    Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials

Related

Read more on YouBank

The Newsroom, ranked for your desk

About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.

  • Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
  • Follow developing storiesAn alert, and a push, the moment a story you follow moves.
  • Your briefing, read aloudA few minutes each morning with a chapter per story.
  • Brief modeSwipe through the day, a 20-second card each.